Adecuación de la solicitud de urocultivos e impacto de sus resultados en el tratamiento de la infección urinaria en Atención Primaria / Adequacy of requesting urine cultures and their impact on urinary tract infection treatment in primary care

No disponible

Artritis séptica por Fusobacterium nucleatum en paciente inmunocompetente / Septic arthritis due to Fusobacterium nucleatum in an immunocompetent patient

No disponible

Lesión ulcerada de evolución rápida en mujer joven / Rapidly progressive ulcerated skin lesion in a young woman

No disponible

[Clinical assessment of Monolisa HCV Ag-Ab ULTRA (Bio-Rad) in a general hospital]. / Evaluación de la técnica Monolisa HCV Ag-Ab ULTRA (BioRad) en un hospital general.

INTRODUCTION: To evaluate a new test based on simultaneous detection of HCV antibodies and antigen (Monolisa HCV Ag/Ab ULTRA; Bio-Rad, Marnes la Coquette, France). METHODS: We studied samples from two groups of patients and 7 commercial HCV seroconversion panels (75 samples). Group 1: 1360 serum samples from patients referred for routine testing of anti HCV antibodies. Group 2: 333 serum samples from 183 hemodialysis patients. All samples were tested by the Ortho HCV 3.0 technique (Ortho-Clinical Diagnostics, Amersham, UK) and the Monolisa HCV Ag-Ab ULTRA technique. RESULTS: Group 1: Seventy-four of 1360 serum samples were positive by Ortho HCV and 77 by Monolisa. In 1353 samples, the results with the two tests were concordant: 1281 negative and 72 positive. Five samples were positive only by Monolisa and 2 only by Ortho (overall agreement: 99.5%). Group 2: Results were concordant in 325 samples, 308 negative and 17 positive. Seven samples were positive by Monolisa and negative by Ortho. The sensitivity of the Monolisa test in hemodialysis patients was clearly higher than that of the Ortho test (100% and 70.8%, respectively). Monolisa detected HCV infection in 43 of 75 samples from the seroconversion panels; only 18 positive samples were detected by Ortho HCV. Monolisa reduced the window period by up to 72 days. CONCLUSIONS: Our data indicate high agreement between the Monolisa and Ortho tests in samples from the general population. In hemodialysis patients, however, Monolisa was more sensitive. In addition, the Monolisa test significantly reduced the window period of HCV infection.

Evaluación de la técnica Monolisa HCV Ag-Ab ULTRA (BioRad) en un hospital general / Clinical assessment of Monolisa HCV Ag-Ab ULTRA (Bio-Rad) in a general hospital

Introducción. Se evaluó una nueva técnica para la determinación simultánea de anticuerpos y antígeno del virus de la hepatitis C (VHC) (Monolisa HCV Ag/Ab ULTRA; BioRad, Marnes la Coquette, France). Métodos. Se estudiaron dos grupos de población y 7 paneles (75 muestras) de seroconversión. Grupo 1: 1.360 sueros con solicitud de determinación de anticuerpos VHC. Grupo 2: 333 sueros de 183 pacientes hemodializados. Las muestras se ensayaron con la técnica Ortho HCV 3.0 (Ortho-Clinical Diagnostics, Amersham, UK) y la técnica Monolisa HCV Ag-Ab ULTRA. Resultados. Grupo 1: en los 1.360 sueros, se obtuvo resultado positivo en 74 casos con la técnica de rutina y en 77 casos con la técnica Monolisa. En 1.353 muestras coincidieron los resultados, 1.281 (­) y 72 (1). Cinco muestras fueron positivas sólo por Monolisa y 2 sólo por Ortho (concordancia global: 99,5%). Grupo 2: 325 muestras dieron resultados coincidentes, 308 (­) y 17 (1). Siete muestras dieron resultado positivo por Monolisa y negativo por Ortho. La sensibilidad de la técnica Monolisa en pacientes hemodializados fue claramente superior a la técnica Ortho (100 y 70,8%, respectivamente). Frente a los paneles de seroconversión la técnica Monolisa detectó 43 muestras positivas frente a las 18 de la técnica de anticuerpos consiguiendo una reducción del período ventana de hasta 72 días. Conclusiones. La técnica Monolisa presentó una elevada concordancia respecto a la técnica Ortho en la población general. En pacientes hemodializados se mostró más sensible que nuestra técnica de rutina. Por otro lado, el período ventana se redujo significativamente (AU)

Introduction. To evaluate a new test based on simultaneous detection of HCV antibodies and antigen (Monolisa HCV Ag/Ab ULTRA; Bio-Rad, Marnes la Coquette, France). Methods. We studied samples from two groups of patients and 7 commercial HCV seroconversion panels (75 samples). Group 1: 1360 serum samples from patients referred for routine testing of anti HCV antibodies. Group 2: 333 serum samples from 183 hemodialysis patients. All samples were tested by the Ortho HCV 3.0 technique (Ortho-Clinical Diagnostics, Amersham, UK) and the Monolisa HCV Ag-Ab ULTRA technique. Results. Group 1: Seventy-four of 1360 serum samples were positive by Ortho HCV and 77 by Monolisa. In 1353 samples, the results with the two tests were concordant: 1281 negative and 72 positive. Five samples were positive only by Monolisa and 2 only by Ortho (overall agreement: 99.5%). Group 2: Results were concordant in 325 samples, 308 negative and 17 positive. Seven samples were positive by Monolisa and negative by Ortho. The sensitivity of the Monolisa test in hemodialysis patients was clearly higher than that of the Ortho test (100% and 70.8%, respectively). Monolisa detected HCV infection in 43 of 75 samples from the seroconversion panels; only 18 positive samples were detected by Ortho HCV. Monolisa reduced the window period by up to 72 days. Conclusions. Our data indicate high agreement between the Monolisa and Ortho tests in samples from the general population. In hemodialysis patients, however, Monolisa was more sensitive. In addition, the Monolisa test significantly reduced the window period of HCV infection (AU)

Colecistitis aguda litiásica asociada a Brucella melitensis / Acute calculous cholecystitis associated with Brucella melitensis

No disponible